Posted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for evaluation by NICE or the new Cancer Drugs Fund.
People with an advanced form of thyroid cancer have to wait up to two to three years before being able to access Lenvima (lenvatinib mesylate) in England, due to failures in the new Cancer Drugs Fund procedure launched on 29 July. Lenvatinib can significantly slow the progression of disease; in its pivotal trial, the treatment provided a significant median progression free survival benefit of 18.3 months versus 3.6 months for placebo (p<0.0001) in radioiodine refractory differentiated thyroid cancer.
